Phase II Study of Irinotecan and Panitumumab as Second-Line Therapy for Patients With Advanced Esophageal Adenocarcinoma.
Phase of Trial: Phase II
Latest Information Update: 17 Nov 2016
At a glance
- Drugs Irinotecan (Primary) ; Panitumumab (Primary)
- Indications Oesophageal cancer
- Focus Therapeutic Use
- 18 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 29 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 22 Jan 2013 Planned End Date changed from 1 Jun 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.